icymi: FDA officials raised conflict of interest concerns ahead of new peptide panel slated to meet this week. Despite the flags, HHS chose multiple panelists who promote peptides, an unusual process given FDA staff typically pick their advisers. wapo.st/4wQFIf9
FDA raised conflict of interest concerns ahead of new peptide panel
That panel will meet to weigh whether the agency should allow Americans to have broader access to seven injectable peptides previously restricted over potential safety concerns.
wapo.st
